| Ident. | Authors (with country if any) | Title |
|---|
| 000084 |
Angela H. Lee [États-Unis] ; Daniel Weintraub [États-Unis] | Psychosis in Parkinson's Disease Without Dementia: Common and Comorbid With Other Non-Motor Symptoms |
| 000137 |
Joseph H. Friedman [États-Unis] | Melperone Is Ineffective in Treating Parkinson's Disease Psychosis |
| 000463 |
Daniel Weintraub [États-Unis] ; David J. Burn [Royaume-Uni] | Parkinson's Disease: The Quintessential Neuropsychiatric Disorder |
| 000602 |
Russell C. Dale [Australie] ; Julian J. Nasti [Australie] ; Greg B. Peters [Australie] | Familial 7q21.3 Microdeletion Involving Epsilon-Sarcoglycan Causing Myoclonus Dystonia, Cognitive Impairment, and Psychosis |
| 000628 |
Stewart A. Factor [États-Unis] ; N. Kyle Steenland [États-Unis] ; Donald S. Higgins [États-Unis] ; Eric S. Molho [États-Unis] ; Denise M. Kay [États-Unis] ; Jennifer Montimurro [États-Unis] ; Ami R. Rosen [États-Unis] ; Cyrus P. Zabetian [États-Unis] ; Haydeh Payami [États-Unis] | Disease-Related and Genetic Correlates of Psychotic Symptoms in Parkinson's Disease |
| 000806 |
Gilles Fenelon [France] ; Thierry Soulas [France] ; Franck Zenasni [France] ; Laurent Cleret De Langavant [France] | The Changing Face of Parkinson's Disease-Associated Psychosis: A Cross-Sectional Study Based on the New NINDS-NIMH Criteria |
| 000B32 |
Javier Virues-Ortega [Espagne] ; Carmen Rodriguez-Blazquez [Espagne] ; Federico Micheli [Argentine] ; Francisco Javier Carod-Artal [Brésil] ; Marcos Serrano-Duenas [Équateur] ; Pablo Martinez-Martin [Espagne] | Cross-Cultural Evaluation of the Modified Parkinson Psychosis Rating Scale Across Disease Stages |
| 000B60 |
Hans-Holger Capelle [Allemagne] ; Christian Blahak [Allemagne] ; Christoph Schrader [Allemagne] ; Hansjörg Baezner [Allemagne] ; Thomas M. Kinfe [Allemagne] ; Jan Herzog [Allemagne] ; Reinhard Dengler [Allemagne] ; Joachim K. Krauss [Allemagne] | Chronic Deep Brain Stimulation in Patients with Tardive Dystonia Without a History of Major Psychosis |
| 000D05 |
Susan H. Fox [Canada] ; Rosalind Chuang [Canada] ; Jonathan M. Brotchie [Canada] | Serotonin and Parkinson's Disease: On Movement, Mood, and Madness |
| 000D36 |
Dagmar Verbaan [Pays-Bas] ; Stephanie M. Van Rooden [Pays-Bas] ; Martine Visser [Pays-Bas] ; Johan Marinus [Pays-Bas] ; Murat Emre [Turquie] ; Jacobus J. Van Hilten [Pays-Bas] | Psychotic and Compulsive Symptoms in Parkinson's Disease |
| 001098 |
Hubert H. Fernandez [États-Unis] ; Dag Aarsland [Norvège] ; Gilles Fenelon [France] ; Joseph H. Friedman [États-Unis] ; Laura Marsh [États-Unis] ; Alexander I. Troster [États-Unis] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Cristina Sampaio [Portugal] ; Glenn T. Stebbins [États-Unis] ; Christopher G. Goetz [États-Unis] | Scales to Assess Psychosis in Parkinson's Disease : Critique and Recommendations |
| 001115 |
Amir Glik [Israël] ; Isabelle Vuillaume [France] ; David Devos [France] ; Rivka Inzelberg [Israël] | Psychosis, Short Stature in Benign Hereditary Chorea : A Novel Thyroid Transcription Factor-1 Mutation |
| 001275 |
Jennifer G. Goldman [États-Unis] ; Christopher G. Goetz [États-Unis] ; Melanie Brandabur [États-Unis] ; Michelle Sanfilippo [États-Unis] ; Glenn T. Stebbins [États-Unis] | Effects of Dopaminergic Medications on Psychosis and Motor Function in Dementia with Lewy Bodies |
| 001432 |
Sergio E. Starkstein [Australie] ; Marcelo Merello [Argentine] | The Unified Parkinson's Disease Rating Scale : Validation Study of the Mentation, Behavior, and Mood Section |
| 001715 |
Bernard Ravina [États-Unis] ; Karen Marder [États-Unis] ; Hubert H. Fernandez [États-Unis] ; Joseph H. Friedman [États-Unis] ; William Mcdonald [États-Unis] ; Diane Murphy [États-Unis] ; Dag Aarsland [États-Unis] ; Debra Babcock [États-Unis] ; Jefferey Cummings [États-Unis] ; Jean Endicott [États-Unis] ; Stewart Factor [États-Unis] ; Wendy Galpern [États-Unis] ; Andrew Lees (neurologue) [Royaume-Uni] ; Laura Marsh [États-Unis] ; Mark Stacy [États-Unis] ; Katrina Gwinn-Hardy [États-Unis] ; Valerie Voon [États-Unis] ; Christopher Goetz [États-Unis] | Diagnostic criteria for psychosis in Parkinson's disease : Report of an NINDS, NIMH work group |
| 001789 |
Martine Visser [Pays-Bas] ; Dagmar Verbaan [Pays-Bas] ; Stephanie M. Van Rooden [Pays-Bas] ; Anne M. Stiggelbout [Pays-Bas] ; Johan Marinus [Pays-Bas] ; Jacobus J. Van Hilten [Pays-Bas] | Assessment of Psychiatric Complications in Parkinson's Disease : The SCOPA-PC |
| 001793 |
Connie Marras [Canada] ; Alexander Kopp [Canada] ; FENG QIU [Canada] ; Anthony E. Lang [Canada] ; Kathy Sykora [Canada] ; Kenneth I. Shulman [Canada] ; Paula A. Rochon [Canada] | Antipsychotic use in older adults with parkinson's disease |
| 001966 |
Naomi P. Visanji [Canada] ; Jordi Gomez-Ramirez [Canada] ; Tom H. Johnston [Canada] ; Donna Pires [Canada] ; Valerie Voon [Canada] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada] | Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease |
| 001989 |
Joseph H. Friedman [États-Unis] ; Robert M. Berman [États-Unis] ; Christopher G. Goetz [États-Unis] ; Stewart A. Factor [États-Unis] ; William G. Ondo [États-Unis] ; Joanne Wojcieszek [États-Unis] ; William H. Carson [États-Unis] ; Ronald N. Marcus [États-Unis] | Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease |
| 001D33 |
Hubert H. Fernandez [États-Unis] ; Martha E. Trieschmann [États-Unis] ; Michael S. Okun [États-Unis] | Rebound psychosis: Effect of discontinuation of antipsychotics in Parkinson's disease |
| 001D78 |
Charles H. Adler [États-Unis] | Nonmotor complications in Parkinson's disease |
| 001E73 |
William G. Ondo [États-Unis] ; Ron Tintner [États-Unis] ; Kevin Dat Voung [États-Unis] ; DEJIAN LAI [États-Unis] ; George Ringholz [États-Unis] | Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease |
| 002109 |
Hubert H. Fernandez [États-Unis] ; Edward M. Donnelly [États-Unis] ; Joseph H. Friedman [États-Unis] | Long-term outcome of clozapine use for psychosis in Parkinsonian patients |
| 002352 |
Werner Poewe [Autriche] | Psychosis in Parkinson's disease |
| 002414 |
Hubert H. Fernandez [États-Unis] ; Martha E. Trieschmann [États-Unis] ; Monica A. Burke [États-Unis] ; Carol Jacques [États-Unis] ; Joseph H. Friedman [États-Unis] | Long-term outcome of quetiapine use for psychosis among parkinsonian patients |
| 002543 |
Christian Prueter [Allemagne] ; Benedikt Habermeyer [Allemagne] ; Christine Norra [Allemagne] ; Christoph M. Kosinski [Allemagne] | Akathisia as a side effect of antipsychotic treatment with quetiapine in a patient with Parkinson's disease |
| 002584 |
Sujana Reddy [États-Unis] ; Stewart A. Factor [États-Unis] ; Eric S. Molho [États-Unis] ; Paul J. Feustel [États-Unis] | The effect of quetiapine on psychosis and motor function in Parkinsonian patients with and without dementia |
| 002789 |
| Drugs to treat dementia and psychosis |
| 002910 |
Paul J. Reading [Royaume-Uni] ; Anna K. Luce [Royaume-Uni] ; Ian G. Mckeith [Royaume-Uni] | Rivastigmine in the treatment of Parkinsonian psychosis and cognitive impairment: Preliminary findings from an open trial |
| 002A33 |
Stewart A. Factor [États-Unis] ; Joseph H. Friedman [États-Unis] ; Margaret C. Lannon [États-Unis] ; David Oakes [États-Unis] ; Keith Bourgeois [États-Unis] | Clozapine for the treatment of drug-induced psychosis in Parkinson's disease : Results of the 12 week open label extension in the PSYCLOPS trial |
| 002B22 |
N. A. Leopold [États-Unis] | Risperidone treatment of drug-related psychosis in patients with Parkinsonism |
| 002B23 |
Erich Mohr [Canada] ; Tilak Mendis [Canada] ; Kathleen Hildebrand [Canada] ; Peter Paul De Deyn [Belgique] | Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: An open pilot trial |
| 002C32 |
H. H. Fernandez [États-Unis] ; M. C. Lannon [États-Unis] ; J. H. Friedman [États-Unis] ; B. P. Abbott [États-Unis] | Clozapine replacement by quetiapine for the treatment of drug-induced psychosis in Parkinson's disease |
| 002C54 |
J. H. Friedman [États-Unis] ; S. A. Factor | Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease |
| 002C87 |
E. S. Molho [États-Unis] ; S. A. Factor [États-Unis] | Worsening of motor features of Parkinsonism with olanzapine |
| 002D30 |
W. Meissner [Allemagne] ; T. Schmidt [Allemagne] ; A. Kupsch [Allemagne] ; T. Trottenberg [Allemagne] ; T. Lempert [Allemagne] | Reversible leucopenia related to olanzapine |
| 002D34 |
H. H. Fernandez [États-Unis] ; J. H. Friedman [États-Unis] ; C. Jacques [États-Unis] ; M. Rosenfeld [États-Unis] | Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease |
| 002D48 |
G. Lera [Argentine] ; J. Zirulnik [Argentine] | Pilot study with clozapine in patients with HIV-associated psychosis and drug-induced Parkinsonism |
| 003161 |
G. Meco [Italie] ; A. Alessandri [Italie] ; P. Giustini [Italie] ; V. Bonifati [Italie] | Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: An open-label, long-term study |
| 003568 |
T. Mendis [Canada] ; E. Mohr [Canada] ; A. George ; I. N. Rusk [Canada] ; P. Gray ; J. D. Grimes | Symptomatic relief from treatment-induced psychosis in Parkinson's disease: an open-label pilot study with remoxipride |
| 003631 |
J. H. Friedman [États-Unis] | Clozapine treatment of psychosis in patients with tardive dystonia: report of three cases |
| 003829 |
S. A. Factor [États-Unis] ; D. Brown | Clozapine prevents recurrence of psychosis in Parkinson's disease |
| 003962 |
R. F. Pfeiffer ; J. Kang ; B. Graber ; R. Hofman ; J. Wilson | Clozapine for psychosis in Parkinson's disease |
| 003A16 |
L. E. Adler ; M. Pecevich ; H. Nagamoto | Bereitschaftspotential in tardive dyskinesia |
